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Abstract
Introduction: Systemic lupus erythematosus (SLE) is a highly heterogeneous disorder, characterized by differences
in autoantibody profile, serum cytokines, and clinical manifestations. SLE-associated autoantibodies and high serum
interferon alpha (IFN-a) are important heritable phenotypes in SLE which are correlated with each other, and play
a role in disease pathogenesis. These two heritable risk factors are shared between ancestral backgrounds. The aim
of the study was to detect genetic factors associated with autoantibody profiles and serum IFN-a in SLE.
Methods: We undertook a case-case genome-wide association study of SLE patients stratified by ancestry and
extremes of phenotype in serology and serum IFN-a. Single nucleotide polymorphisms (SNPs) in seven loci were
selected for follow-up in a large independent cohort of 538 SLE patients and 522 controls using a multi-step
screening approach based on novel metrics and expert database review. The seven loci were: leucine-rich repeat
containing 20 (LRRC20); protein phosphatase 1 H (PPM1H); lysophosphatidic acid receptor 1 (LPAR1); ankyrin repeat
and sterile alpha motif domain 1A (ANKS1A); protein tyrosine phosphatase, receptor type M (PTPRM); ephrin A5
(EFNA5); and V-set and immunoglobulin domain containing 2 (VSIG2).
Results: SNPs in the LRRC20, PPM1H, LPAR1, ANKS1A, and VSIG2 loci each demonstrated strong association with a
particular serologic profile (all odds ratios > 2.2 and P < 3.5 × 10
-4). Each of these serologic profiles was associated
with increased serum IFN-a. SNPs in both PTPRM and LRRC20 were associated with increased serum IFN-a
independent of serologic profile (P = 2.2 × 10
-6 and P = 2.6 × 10
-3 respectively). None of the SNPs were strongly
associated with SLE in case-control analysis, suggesting that the major impact of these variants will be upon
subphenotypes in SLE.
Conclusions: This study demonstrates the power of using serologic and cytokine subphenotypes to elucidate
genetic factors involved in complex autoimmune disease. The distinct associations observed emphasize the
heterogeneity of molecular pathogenesis in SLE, and the need for stratification by subphenotypes in genetic
studies. We hypothesize that these genetic variants play a role in disease manifestations and severity in SLE.
* Correspondence: tniewold@medicine.bsd.uchicago.edu
1University of Chicago Pritzker School of Medicine, Section of Rheumatology
and Gwen Knapp Center for Lupus and Immunology Research, 924 E. 57th
St., Chicago, IL, 60637, USA
Full list of author information is available at the end of the article
Kariuki et al. Arthritis Research & Therapy 2010, 12:R151
http://arthritis-research.com/content/12/4/R151
© 2010 Kariuki et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Introduction
Systemic lupus erythematosus ((SLE) OMIM #152700) is a
complex disease characterized by multi-system involve-
ment commonly affecting the skin, renal, musculoskeletal,
and hematopoetic systems. SLE is caused by interactions
between susceptibility genes and environmental factors
resulting in an irreversible loss of immunologic self-
tolerance [1]. Incidence is highest in women during the
reproductive years [2]; however, people of all ages, gen-
ders, and ancestral backgrounds are susceptible. Disease
features range from typically reversible manifestations
such as rash or inflammatory arthritis to life-threatening
end-organ damage such as glomerulonephritis or throm-
bosis, and it is difficult to predict which manifestations
will affect an individual patient.
Interferon alpha (IFN-a) is a pleiotropic type I inter-
feron with the potential to break immunologic self-toler-
ance by activating antigen-presenting cells after uptake
of self material [3]. Serum IFN-a is elevated in many
SLE patients, and elevations often correlate with disease
activity [4,5]. Recombinant human IFN-a administered
as a therapy for chronic viral hepatitis and malignancy
is thought to cause de novo SLE in some patients [6].
IFN-a-induced SLE typically resolves after the IFN-a is
discontinued [7,8], supporting the idea that IFN-a was
c a u s a l .W eh a v ep r e v i o u s l ys h o w nt h a ts e r u mI F N - a is
abnormally high in 20% of healthy first degree relatives
of SLE patients as compared to < 5% of healthy unre-
lated individuals [9]. Spouses of SLE patients did not
have high serum IFN-a. Taken together, these data sug-
gest that high serum IFN-a is a heritable risk factor for
SLE. Additionally, serum IFN-a activity is highest dur-
ing the ages of peak SLE incidence in both patients and
their healthy first degree relatives [10]. The high IFN-a
trait in SLE families is inherited in a complex fashion,
suggesting polygenic inheritance which has not been
fully characterized [11].
Autoantibodies directed at double-stranded DNA
(dsDNA) and RNA binding proteins (anti-Ro, anti-La,
anti-Sm, and anti-RNP, collectively anti-RBP) are char-
acteristically found in SLE sera, and are the strongest
known predictors of high serum IFN-a in SLE patients
[9]. The presence of anti-RBP and anti-dsDNA autoanti-
bodies appears to be heritable in SLE families [12].
These autoantibodies are rare in healthy first degree
relatives (one to three percent prevalence), and thus her-
itability of autoantibody traits is not sufficient to explain
the heritability of high serum IFN-a in SLE families [9].
Immune complexes formed by these SLE-associated
autoantibodies can directly stimulate IFN-a production
in vitro, likely via the endosomal Toll-like receptors
[13]. In humans in vivo, we find that while anti-RBP
antibodies are associated with high serum IFN-a,t h e y
are not sufficient [14]. This suggests that although these
SLE-associated autoantibodies are correlated and likely
mechanistically related to serum IFN-a,o t h e rf a c t o r s
such as genetic variation will likely be important to in
vivo IFN-a levels.
We have begun to genetically map the high IFN-a
trait in SLE, and found that a number of genetic var-
iants which are associated with susceptibility to SLE are
also associated with increased serum IFN-a,i n c l u d i n g
variants of interferon regulatory factor 5 (IRF5) [15],
interferon regulatory factor 7 (IRF7) [16], protein tyro-
sine phosphatase non receptor type 22 (PTPN22)[ 1 7 ] ,
and osteopontin (SPP1)[ 1 8 ] .W eh a v ea l s os h o w nt h a t
the autoimmune disease associated variant of signal
transducer and activator of transcription 4 (STAT4)
modulates cellular sensitivity to IFN-a signaling [19].
These studies provide further support for the hypothesis
that IFN-a pathway dysregulation is a primary causal
factor in human SLE. This work also suggests that the
serum IFN-a trait could be a useful tool in identifying
additional genetic loci related to SLE pathogenesis.
In this study, we performed a genome-wide association
study (GWAS) on 104 SLE patients stratified by extremes
of phenotype in serum IFN-a. Given the importance of
anti-RBP and anti-dsDNA antibodies on serum IFN-a,
patients were also stratified by the presence or absence of
these antibodies. The size of the GWAS study did not
allow for rigorous exclusion of false positives, so we used
a multi-step screening algorithm which included novel
metrics derived from the GWAS chip data and expert lit-
erature and database review to increase the likelihood of
selecting true positive SNPs for validation. SNPs selected
were then genotyped in an independent SLE cohort, test-
ing for association with autoantibody profile and serum
IFN-a in a case-case study design, as well as overall asso-
ciation with SLE in a case-control study. This approach
was chosen to maximize our opportunity for novel gene
discovery in a moderate-sized well-characterized cohort
with complete molecular phenotype data. The trait-strati-
fied GWAS screening approach followed by selected vali-
dation was successful, and we report seven novel loci
which are strongly associated with autoantibodies and
serum IFN-a, two important heritable subphenotypes in
SLE.
Materials and methods
Patients and samples
The initial cohort of SLE patients studied in the GWAS
scan was obtained from the Hospital for Special Surgery
Lupus Registry, and consisted of 104 SLE patients,
including 20 African-American, 36 European-American,
32 Hispanic-American, and 16 Asian-American SLE
patients. Patients were selected from the top 33% and
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ally stratified by ancestry and the presence or absence of
anti-RBP or anti-dsDNA antibodies. The independent
validation cohort of 538 SLE patients was obtained from
the University of Chicago Translational Research in the
Department of Medicine (TRIDOM) registry and Rush
University Medical Center, and consisted of 280 Afri-
can-American, 173 European-American, and 85 Hispa-
nic-American SLE patients. The validation cohort was
not selected for inclusion in the study based upon any
particular SLE-associated phenotype. All patients met
the revised 1982 American College of Rheumatology cri-
teria for the diagnosis of SLE [20]. Samples from 522
controls were obtained from the TRIDOM registry,
including 361 African-American and 161 European-
American subjects who were individually screened for
the absence of autoimmune disease by medical record
review and matched by sex to the cases. The controls
were on average older than the cases, although given
our ability to screen for the absence of autoimmune dis-
ease this should be of benefit as one would assume that
older individuals who do not have autoimmune disease
are likely a low-risk group for autoimmunity. Clinical
characteristics and demographic information for the
patients and controls in the validation cohort are sum-
marized in Supplemental table S1 in Additional file 1.
Informed consent was obtained from all subjects at each
site, and the study was approved by the institutional
review board at each institution.
Measurement of serum IFN-a activity and autoantibodies
The reporter cell assay for IFN-a has been described in
detail elsewhere [9,21]. In brief, reporter cells (WISH
cells, ATCC #CCL-25) were used to measure the ability
of patient sera to cause IFN-induced gene expression.
The output of the assay is interpreted as a functional
activity of IFN-a in the serum sample. Results from the
IFN-a assay were standardized to a healthy multi-ances-
tral reference population as previously described, and a
serum IFN-a activity score was calculated based upon
the mean and SD of the reference population [9]. Anti-
bodies to anti-Ro, anti-La, anti-Sm, and anti-RNP were
measured in all samples by ELISA methods, and anti-
dsDNA antibodies were measured using Crithidia luci-
liae immunofluorescence, with detectable fluorescence
considered positive. Autoantibodies were assayed in the
TRIDOM and Rush University samples in the University
of Chicago clinical laboratory, and the Hospital for Spe-
cial Surgery samples used in the GWAS screening were
assayed in the Hospital for Special Surgery clinical
laboratory. Standard clinical lab cutoff points were used
to categorize samples as positive or negative. There
were no significant differences in autoantibody preva-
lence between the two clinical laboratories.
Screening GWAS study
The initial cohort of SLE patients studied in the GWAS
scan consisted of 104 SLE patients obtained from the
Hospital for Special Surgery Registry. A study design
incorporating multiple ancestral backgrounds was cho-
sen, as both autoantibodies and serum IFN-a levels are
heritable pathogenic factors which are shared between
all ancestral backgrounds [9,12]. This does not ensure
that the same factors will underlie the serum IFN-a
trait in all backgrounds, and we considered each ances-
tral background separately in the GWAS. Patients were
selected in an “extremes of phenotype” design from the
top 33% and bottom 33% of serum IFN-a activity, and
were additionally stratified by ancestry and the presence
or absence of anti-RBP or anti-dsDNA antibodies.
Genomic DNA from SLE patients in the HSS registry
was combined into pools of four individuals matched by
ancestry, IFN-a levels, and presence or absence of anti-
RBP or anti-dsDNA autoantibodies, respectively. The
high IFN-a group was defined as those patients in the
top 33% of serum IFN-a who had one or more of the
following autoantibody specificities: Ro, La, Sm, RNP, or
dsDNA, and the low group was defined as those in the
bottom 33% of serum IFN-a who lacked these autoanti-
bodies. These pools containing equal amounts of DNA
from four individuals matched by these traits were run
on Affymetrix 500K SNP mapping chips (Santa Clara,
CA, USA) per manufacturer protocol. Data from the
individual probes were then analyzed, and probe inten-
sity was used to represent allelic frequencies present in
the pooled DNA. Probe data were summarized and ana-
lyzed using Gene Pool by Pearson JV et al.[ 2 2 ] .W e
considered two metrics to help identify allele frequency
differences between the high vs. low IFN-a groups and
the present vs. absent anti-RBP or anti-dsDNA groups.
The first metric is the Silhouette score proposed by
Pearson et al. [22].
We also developed our own score which is the differ-
ence in the weighted mean of the relative allele signals
(RAS = intensity of A allele/(intensity of A + intensity
of B allele)) for each ethnic group (EA, AA, HI). The
weights were constructed as the inverse standard devia-
tion of the RAS score calculated from the 8 (or 12)
probes per SNP present on the Affymetrix array. The
weights were then normalized so that they sum to one.
Our adjusted RAS score is then calculated by summing
each group’s weighted RAS score. The goal of construct-
ing our own statistic was three-fold: First, it down-
weighted SNPs that had highly variable signals even if
the mean differences between groups was large; this
allows a certain measure of quality control that is not
offered as effectively by the Silhouette score; second, it
accounts for heterogeneity of allele frequencies among
the ancestral groups; third, it creates a statistic that is
Kariuki et al. Arthritis Research & Therapy 2010, 12:R151
http://arthritis-research.com/content/12/4/R151
Page 3 of 12robust to population stratification which can lead to
false positives.
Specifically, the weighted mean RAS score is calcu-
lated as follows:
Define ri,j,k = RAS score for the j
th c o n t r o l( i=0 )o r
case (i = 1) of ethnicity k = {EA, AA, Asian, HA}, vi,j,k =
variance of the i,j,k
th RAS score.
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Of the 104 subjects studied in the GWAS, 44 were in
the high IFN-a/autoantibody positive group and 60
were in the low IFN-a/autoantibody negative group. It
was difficult to match even numbers of subjects between
these two groups in each ancestral background due to
the stringent double phenotype case selection criteria,
and some of the ancestral groups deviated from a 1:1
match (proportions by ancestral background were as fol-
lows: Asian-American 8 high and 8 low, African-Ameri-
can 12 high and 8 low, European-American 12 high and
24 low, Hispanic-American 12 high and 20 low). This
was not confounding, as the data from each ancestral
background were analyzed separately.
Selection of SNPs from GWAS study for validation
We next employed a multiple step screening algorithm
to select a subset of SNPs for replication that were
highly suggestive based on both their Silhouette and
weighted RAS scores. SNPs were first ordered by
weighted RAS score, and the top 200 SNPs by RAS
score were considered. SNPs on this list with a Silhou-
ette score that was not within the top 200 Silhouette
scores were removed (31%), leaving SNPs that ranked in
the top 200 by both metrics. These remaining SNPs
were again ranked by weighted RAS score, and the loca-
tion of each of the top 50 SNPs was examined in detail
(Supplemental table S2 in Additional file 1). Similar to
other autoimmune diseases, SNPs which are associated
with SLE in unbiased genome-wide mapping studies are
largely within or near genes with immune system func-
tion [23], and we presumed that our study design which
stratified patients by two immune system phenotypes
would likely yield SNPs in genes related to the immune
system. Therefore, we assumed that the prior probability
of a true association was increased if 1) the SNP was
located within or near a known gene, and 2) if that
locus had immune system relevance based upon public
databases. Nine SNPs of the top 50 met both of these
criteria (Supplementary table S2 in Additional file 1).
SNP genotyping in the validation cohort
Individuals in the validation cohort were genotyped at the
following SNPs using ABI Taqman Assays-by-Design pri-
mers and probes: rs10762360 (leucine-rich repeat con-
taining 20, LRRC20), rs10784318 (protein phosphatase 1
H, PPM1H), rs10980684 (lysophosphatidic acid receptor
1, LPAR1), rs2820223 (ankyrin repeat and sterile alpha
motif domain containing 1A, ANKS1A), rs17494870 (pro-
tein tyrosine phosphatase, receptor type M, PTPRM),
rs26725 (ephrin A5, EFNA5), and rs112219769 (V-set
and immunoglobulin domain containing 2, VSIG2). Scat-
ter plots were all reviewed individually for quality, and
none of the SNPs genotyped deviated significantly from
the expected Hardy-Weinberg proportions (P >0 . 0 1f o r
all SNPs in all ancestral backgrounds). Each SNP assay
resulted in successful genotype calls in > 98% of the sub-
jects, and none of the cases or controls were excluded
due to incomplete or unsuccessful genotyping.
Statistical analysis in validation cohort
Logistic regression models were used to detect associa-
tions between the presence of autoantibodies and geno-
type at candidate SNPs. We performed this analysis
because the initial GWAS study was stratified by both
serum IFN-a and autoantibodies, and we sought to
detect and clarify any potential associations with serology.
Screening models incorporated each of the SNPs as pre-
dictor variables with a single autoantibody trait as the
outcome variable in each ancestral background separately,
and backward step-wise regression was performed dis-
carding predictors which did not show evidence for asso-
ciation (P > 0.1). When more than one SNP was
significantly associated with a particular antibody, interac-
tion terms were included to detect potential SNP-SNP
interactions. SLE-associated autoantibodies can show
associations with other autoantibodies, (for example, the
presence of anti-Sm is highly correlated with the presence
of anti-RNP) and so we undertook additional logistic
regression modeling to explore and refine SNP-antibody
associations if one allele of a SNP was associated more
strongly with a combination of antibodies than with
either antibody alone. To test combination models, we
generated new outcome variables which represented a
combination of the two associated autoantibodies based
upon the direction of the associations observed in the
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anti-dsDNA vs. the absence of one or both of those anti-
bodies). If the antibody combination outcome variable
provided significantly improved fit as compared to the
individual autoantibody outcome variables, then the com-
bination was reported as the best fit model.
To account for potential differences in admixture or
population structure within self-reported ancestral back-
grounds in the validation cohort, we performed a principal
component analysis which included 13 independent SNPs
(including the seven described in this study) that had been
genotyped in all of our cases and controls. The first com-
ponent obtained in this analysis provided a strong separa-
tion between subjects of self-reported African-American
ancestry and self-reported European-American ancestry.
Using the central value for this component to categorically
split the population into African-derived vs. European-
derived ancestry bins, self-reported African-American sub-
jects were concordant with the African-derived ancestry
bin 75.1% of the time, and self-reported European-Ameri-
cans were concordant with the European-derived ancestry
bin 86.3% of the time (P-value for a random distribution
of self-reported ancestral backgrounds between these two
bins = 1.3 × 10
-91). Self-reported Hispanic-American
ancestry subjects were largely overlapping with the Eur-
opean-American subjects in this analysis. We retested our
autoantibody regression models and case-control analyses
incorporating the first principal component as a quantita-
tive covariate designating proportional European- vs. Afri-
can-derived ancestry, and did not find significant
differences in autoantibody associations with or without
the inclusion of the first principal component in the
regression (data not shown). The lack of a significant
impact upon the reported associations provides some reas-
surance that these associations are not the result of differ-
ences between cases and controls in proportional
admixture or population structure differences within self-
reported ancestral backgrounds.
To analyze serum IFN-levels in the context of SNP
genotype, column graphs were constructed to compare
quantitative IFN-a levels between genotype categories.
Because IFN-a levels were far from normally distributed,
we used a non-parametric version of the two sample t-
test (non-parametric Mann-Whitney U) to test if IFN-a
levels varied significantly between two SNP genotype
groups. Case-control allele frequency differences were
tested using a chi-square test of independence. Reported
P-values are not adjusted for multiple comparisons.
Results
Results of GWAS screening study and multi-step
screening algorithm
The top 50 SNPs from the screening GWAS study were
determined using a combination of their Silhouette and
weighted RAS scores (see Methods, Supplemental table
S2 in Additional file 1), and we examined each of these
SNPs in detail. When a SNP was located within or near
a gene, a comprehensive literature and public database
search was performed on each gene. We assumed that
the prior probability of a true association was increased
if, 1) the SNP was located within or near a known gene,
and 2) if that locus had immune system relevance based
upon public databases. Nine SNPs located in or near the
following eight genes met both criteria: STAT4,
LRRC20, PPM1 H, LPAR1, ANKS1A, PTPRM, EFNA5,
and VSIG2. Two SNPs in the top 50 were located in the
ANKS1A region, and in this case the SNP that was sta-
tistically stronger in the GWAS study was chosen for
validation. The SNP in STAT4 (rs9967792) was located
in the third intron of the gene. This SNP is in the LD
block immediately adjacent to the SLE-associated haplo-
type block of STAT4 [24,25]. We have previously
demonstrated that variati o ni nt h i st h i r di n t r o no f
STAT4 was associated with both serum IFN-a and auto-
antibody profile in multiple ancestral backgrounds in a
study which included some of the same individuals [19],
and we presumed that this was a recapitulation of that
result, and did not pursue this SNP. Finding STAT4 in
the top 50 SNPs demonstrated that true positive SNPs
were indeed included among the top 50 in our screening
GWAS study. Statistical results from the GWAS in each
ancestral background separately for the seven SNPs cho-
sen for validation are shown in Supplemental table S3 in
Additional file 1.
Association of GWAS candidates with serologic subsets in
SLE
Individuals in the validation cohort were genotyped at the
following SNPs: rs10762360 (LRRC20), rs10784318
(PPM1H), rs10980684 (LPAR1), rs2820223 (ANKS1A),
rs17494870 (PTPRM), rs26725 (EFNA5), and rs112219769
(VSIG2). We used logistic regression models to test candi-
date SNPs from the initial GWAS for potential serologic
associations in the validation cohort. SLE-associated auto-
antibodies can show associations with other autoantibo-
dies, and so if one SNP was associated with more than one
antibody we undertook additional logistic regression mod-
eling to explore genetic associations with antibody combi-
nations (see Methods). Output from the initial screening
and follow up models is reported for each ancestral back-
ground separately in Supplemental tables S4-6 in Addi-
tional file 1. These regressions identified strong serologic
associations for five of the seven SNPs which were surpris-
ingly diverse, both in the specific associated autoantibody
profile as well as the particular ancestral background
(Table 1). Many of these serologic associations were
very strong with OR > 2.0, and five of the seven SNPs
had P-values which exceeded a Bonferroni threshold of
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-3, allowing for correction for both the number of
SNPs tested and the number of traits considered. No
SNP-SNP interactions were detected. Alleles of the SNPs
in both LPAR1 and ANKS1A were associated with more
than one autoantibody in the initial regressions, and fol-
low-up regression analysis supported a best-fit model in
which these alleles were associated with the presence of
the two autoantibodies simultaneously. The VSIG2
rs112219769 T allele showed a positive association with
anti-RNP antibodies and an inverse association with anti-
Sm antibodies. This was surprising, as the presence of
anti-Sm autoantibodies is correlated with the presence of
anti-RNP antibodies. The best-fit model for the VSIG2
SNP was achieved with the antibody profile anti-RNP posi-
tive, anti-Sm negative.
Association of GWAS candidates with serum IFN-a activity
in the SLE cohort
We next tested for relationships between SNP genotype
at the candidate SNPs and serum IFN-a in the SLE
patients in the validation cohort. Genotype at the SNPs
in PTPRM and LRRC20 showed a statistically significant
relationship with serum IFN-a in SLE patients when
ancestral backgrounds were analyzed in aggregate
(P =2 . 2×1 0
-6 and P =2 . 6×1 0
-3 respectively, both
exceeding Bonferroni threshold P-value of 7.1 × 10
-3,
Figure 1). The C allele of rs17494870 (PTPRM)d i dn o t
show any evidence for association with serologic profile,
however this allele was the most strongly associated
with serum IFN-a, and the association was indepen-
dently observed in multiple ancestral backgrounds
(Supplemental figure S1 in Additional file 1). In African-
Americans, we had observed an association between the
LRRC20 rs10762360 G allele and anti-La, but surpris-
ingly we found no association between genotype at this
SNP and IFN-a in African-Americans. Instead, there
was a highly significant relationship between serum
IFN-a and LRRC20 genotype in a joint analysis of Eur-
opean- and Hispanic-American subjects (P = 2.1 × 10
-4),
in whom the serologic association with anti-La antibo-
dies was not present (Supplemental figure S2 in Addi-
tional file 1). The SNPs in PPM1 H, LPAR1, ANKS1A,
and VSIG2 genes did not demonstrate a relationship
with serum IFN-a, however the antibody profiles asso-
ciated with these genes were strongly associated with
increased serum IFN-a, suggesting a secondary associa-
tion (Figure 2). A distinct pattern of association was
observed between the SNP in the EFNA5 locus and
serum IFN-a.T h eEFNA5 rs26725 C allele was asso-
ciated with increased IFN-a only in those subjects who
had anti-RNP antibodies, suggesting a cooperative effect
between the rs26725 C allele and anti-RNP antibodies
upon serum IFN-a (Figure 2e). While we have pre-
viously shown that serum IFN-a is higher in younger
SLE patients, none of the SNPs tested were significantly
associated with age of the subjects, and thus age should
not be driving the differences we observed related to
SNP genotype.
The different patterns of association between these
SNPs and serum IFN-a and autoantibody traits were
striking, and allowed us to place pathogenic events in
order to some degree (Figure 3). The patterns observed
could be summarized into two major categories as they
relate to serum IFN-a: one in which the gene exerts an
influence on serum IFN-a independent of any autoanti-
body association (PTPRM and LRRC20), and a second
pattern in which the gene is associated with serum IFN-
a secondarily due to an association with an autoanti-
body profile that is characterized by high IFN-a
(PPM1H, ANKS1A, LPAR1, VSIG2). A third pattern of
Table 1 Serologic associations observed in SLE patients in the replication cohort, best fit model from logistic
regression
Locus and Allele Associated Antibody Profile Ancestral Background Odds Ratio (95% CI) P-value
LRRC20 rs10762360 G Anti-La AA 2.40
(1.51 to 3.81)
1.6 × 10
-4
PPM1 H rs10784318 C Anti-La EA and HA joint 3.74
(1.88 to 7.47)
3.6 × 10
-5
LPAR1 rs10980684 T Anti-Ro with Anti-Sm AA and HA joint 2.22
(1.42 to 3.47)
1.2 × 10
-4
ANKS1A rs2820223 C Anti-Ro with Anti-dsDNA AA 3.14
(1.68 to 5.87)
3.5 × 10
-4
PTPRM rs17494870 C - - - -
EFNA5 rs26725 C Anti-RNP AA 1.73
(1.10 to 2.72)
0.018
VSIG2 rs11219769 T Anti-RNP lacking Anti-Sm EA and HA joint 3.99
(1.81 to 8.75)
2.1 × 10
-4
AA, African-American, EA, European-American, HA, Hispanic-American, 95% CI, 95% confidence interval; “joint” indicates that two or more ancestral backgrounds
showed a similar tendency when analyzed separately with a non-significant difference observed between odds ratios, and that the indicated ancestral
backgrounds were analyzed jointly using a fixed-effects model.
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which IFN-a was significantly increased only when the
particular allele and specific autoantibody are found
together. This was similar to the pattern we had
observed with the SLE-associated variants of IRF5 and
IRF7 [15,16].
Case-control Association Study of the Seven Candidate
loci from GWAS
There were no significant differences in allele frequen-
cies between SLE cases and non-autoimmune controls
in overall case-control analyses in African- and Eur-
opean-American ancestral backgrounds (Supplemental
table S7 in Additional file 1). Differences in allele fre-
quencies for each SNP in each ancestral background
were modest (most ORs were in the 0.8 to 1.2 range).
T h es i z eo fo u rc a s e - c o n t r o l populations do not allow
us to exclude the possibility that an association exists,
b u ti ta p p e a r st h a tt h em o s td r a m a t i cg e n e t i ce f f e c t s
observed with these SNPs in SLE will be upon
subphenotypes.
Discussion
In this study, we used a detailed subphenotyping strat-
egy to detect genetic factors associated with two impor-
tant heritable phenotypes in SLE: autoantibody traits
and serum IFN-a activity. Both of these traits have been
associated with increased disease activity in SLE [5,26],
and both are thought to play a pathogenic role in dis-
ease initiation [9,27]. The number and strength of the
genetic associations discovered suggests that this techni-
que could be a powerful tool in other diseases. A ver-
sion of this study design has been used in rheumatoid
arthritis, as patients are often stratified by the presence
or absence of anti-cyclic citrullinated peptide antibodies,
and large differences in genetic associations between
these two serologic subsets have been observed [28].
T h es e v e nl o c it h a tw ef o u n dt ob es t r o n g l ya s s o c i a t e d
with subphenotypes in SLE could potentially be discov-
ered in a large case-control study, however these loci
would likely be characterized by modest odds ratios for
association in a traditional case-control study design
based upon our case-control data. A limitation of our
s t u d yi st h a tw ed i dn o th a v ec o m p l e t ec l i n i c a ld a t a
available for all of the cases in the study, and thus we
did not attempt to detect associations with clinical fea-
tures of disease. Another limitation is that we did not
have dense ancestry-informative genetic markers avail-
able in our cohort, and the pooled design of the GWAS
study limited to some degree the amount of ancestry-
related genetic information obtained from individual
Figure 1 Serum IFN-a levels in SLE patients stratified by SNP
genotype at PTPRM (a) and LRRC20 (b). Y-axis shows the serum
IFN-a activity score as outlined in the Methods section. Bars show
the median, error bars show the interquartile range. Because IFN-a
levels were far from normally distributed, we used a non-parametric
version of the two sample t-test (non-parametric Mann-Whitney U)
to test if IFN-a levels varied significantly between the two
homozygous genotype groups.
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Page 7 of 12Figure 2 Serum IFN-a levels in SLE patients stratified by genotype at PPM1 H (a), LPAR1 (b), ANKS1A (c), VSIG2 (d), and EFNA5 (e).
Minor allele homozygotes are combined with heterozygotes for analysis. Patients are stratified first by genotype, and secondarily by the
serologic factor associated with the particular SNP in Table 1, as indicated in the legend below the X-axis. Y-axis shows the serum IFN-a activity
score as outlined in the Methods section. Bars show the median, error bars show the interquartile range. P-values indicate two column
comparisons between the bars on the graph indicated by the line, and are calculated using the Mann-Whitney U test. Significant differences are
observed either between subjects with the same genotype but with differing serological profiles (a through d), or between subjects with
different genotypes but sharing the same serologic profile (e).
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Page 8 of 12subjects in the GWAS portion of the study. As noted in
the Methods, we tested associations within each self-
reported ancestral background separately, used statistics
that are robust to differences related to ancestry in the
GWAS meta-analysis, and also used statistical methods
to address potential confounding by differences in pro-
portional ancestry within self-reported ancestral groups
in the validation cohort. These analyses did not suggest
that our results were confounded by ancestry. Follow-up
replication and fine-mapping studies of these seven loci
in independent multi-ancestral cohorts with dense
ancestry-informative markers would be warranted.
The SNPs examined in this study are located in or
near genes which are both novel in their association
with SLE and highly interesting as potential immunomo-
dulatory loci. The LRRC20 gene product has not been
studied to date, but is known to contain leucine-rich
repeats which are similar to the Toll-like receptor family
of proteins involved in microbial pattern sensing and sti-
mulation of cytokine pathways, including the IFN-a
pathway. PTPRM is a receptor-type protein tyrosine
phosphatase [29], which is of particular interest as a
number of protein tyrosine phosphatases have been
linked to autoimmune disease, including PTPN22 and
PTPN2 [1,30]. PTPRM mediates cell-cell aggregation via
its extracellular domain [29], and the phosphatase
domain allows intra-cellular signaling. PPM1 H is an
intra-cellular phosphatase which is involved in regula-
tion of apoptosis, possibly via the p53 pathway [31].
LPAR1 and EFNA5 encode receptors expressed on leu-
kocytes which can mediate apoptosis and chemotaxis
[32], and leukocyte adhesion [33] respectively. Interest-
ingly, genetic variation 124 kb upstream of LPAR1 was
recently associated with circulating monocyte count in
European populations [34]. ANKS1A is also expressed in
leukocytes and can be phosphorlyated by Lck [35], sug-
gesting a potential role in T-cell signaling. After comple-
tion of our study, a SNP near ANKS1A in the
immediately adjacent UHRF1 binding protein 1
(UHRF1BP1) locus was reported to confer modest risk
of SLE (OR = 1.17) in a large case-control study in Eur-
opean ancestry [36]. While we observed the major asso-
ciation between ANKS1A and SLE phenotype in
African-Americans, it is possible that with a larger Eur-
opean ancestry cohort we may have observed an asso-
ciation between this locus and SLE phenotype, and this
genomic region clearly warrants further study in multi-
ple ancestral backgrounds. VSIG2,a l s ok n o w na s
Figure 3 Diagrams of the patterns of association observed between SNP genotype, serologic profile, and serum IFN-a. “Gene”
represents the genetic variation in the locus studied, and “Ab” represents the particular serologic profile associated with that locus. Connecting
lines between nodes indicate associations, and arrowheads show the hypothesized direction of the relationship. The loci demonstrating each
pattern are indicated following the letter labeling the panel. The dashed line in C. indicates that a suggestive association was seen between the
EFNA5 SNP genotype and the same serologic profile which is linked to IFN-a, but this serologic association did not withstand Bonferroni
correction for multiple comparisons.
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Page 9 of 12cortical thymocyte receptor like, is expressed in the thy-
mus and may be involved in antigen presentation [37].
There are no known direct physical interactions between
these gene products, although functionally each of these
genes converge upon important immune system features
involved in SLE pathogenesis, such as cell-cell interac-
tion, antigen responses, and apoptosis.
Of the SLE risk loci which have previously been asso-
ciated with serum IFN-a levels in SLE patients
[15-19,38], only STAT4 was represented in our top 50
SNP list. It is important to note that our screening
GWAS study was not powered to exclude potential
associations with serum IFN-a in SLE with any degree
of certainty, and absence of a gene from our list does
not mean that it cannot be associated with serum IFN-a
phenotype in SLE. We were encouraged that one of
these previously reported IFN-a-associated loci was pre-
sent in the top 50 list, supporting the idea that we were
able to identify some true positives. We would estimate
that many more loci will be associated with the serum
IFN-a phenotype in SLE, and this study is by no means
exhaustive. It is interesting that the human leukocyte
antigen (HLA) locus was not represented in our list of
top SNPs, as this locus is known to be one of the stron-
gest associations with SLE and many other autoimmune
diseases [23,39]. Different HLA alleles are known to be
associated with particular autoantibody profiles in SLE
[40]. The HLA locus is highly complex and shows a
large degree of variation by ancestry, and it is possible
that the multi-ancestral nature of our screening GWAS
cohort did not allow detection of HLA associations.
The success of this study design suggests that applica-
tion of a similar technique in other diseases could be
highly advantageous, allowing for robust gene discovery
related to important pathways and subphenotypes using
a smaller cohort than is typically studied in case-control
GWAS. Additionally, we demonstrate a number of dif-
ferent patterns of association between SNP genotype
and molecular subphenotypes (Figure 3). These intricate
subphenotype relationships begin to suggest pathogenic
models, which can be followed up in mechanistic stu-
dies. This is another strength of this study design, as
more information regarding the potential function and
role in disease pathogenesis is immediately available for
the candidate genes as compared to standard case-
control designs. The models outlined in Figure 3 can be
tested functionally, allowing for integration of these loci
into the mechanisms of human SLE pathogenesis.
Conclusions
We compare patients from the extremes of high vs. low
interferon and autoantibody levels, and identify a num-
ber of novel genetic regions that are associated with
high interferon alpha and particular autoantibodies in
SLE patients. These genetic associations were very
strong in the particular patient groups who demon-
strated the specific findings and were not as strong in
the overall cohort, suggesting that this approach was
necessary to discover these genes. These genotype-phe-
notype relationships begin to suggest pathogenic models,
which can be followed up in mechanistic studies and
allow these genes to be integrated into the framework of
human SLE pathogenesis. The number and strength of
the genetic associations discovered suggests that this
technique could be a powerful tool in other diseases.
Because both autoantibody profile and serum IFN-a are
important heritable pathogenic factors in SLE, we
hypothesize that the gene variants we describe will play
a role in disease susceptibility and severity in SLE.
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